Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
The price of Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) closed at $22.41 in the last session, down -0.27% from day before closing price of $22.47. In other words, the price has decreased by -$0.27 from its previous closing price. On the day, 0.72 million shares were traded. CNTA stock price reached its highest trading level at $22.77 during the session, while it also had its lowest trading level at $21.78.
Ratios:
We take a closer look at CNTA’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 10.12 and its Current Ratio is at 10.12. In the meantime, Its Debt-to-Equity ratio is 0.34 whereas as Long-Term Debt/Eq ratio is at 0.34.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of . The stock’s future direction. In the most recent recommendation for this company, Wells Fargo on September 03, 2025, initiated with a Overweight rating and assigned the stock a target price of $31.
On July 21, 2025, Truist started tracking the stock assigning a Buy rating and target price of $30.Truist initiated its Buy rating on July 21, 2025, with a $30 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Sep 24 ’25 when Bush Tia L sold 35,000 shares for $24.00 per share. The transaction valued at 840,000 led to the insider holds 121,503 shares of the business.
Bush Tia L bought 35,000 shares of CNTA for $840,000 on Sep 24 ’25. On Sep 16 ’25, another insider, Accardi Mario Alberto, who serves as the President, Orexin Program of the company, sold 8,172 shares for $21.40 each. As a result, the insider received 174,846 and left with 197,394 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CNTA now has a Market Capitalization of 3004585728 and an Enterprise Value of 2872002816. For the stock, the TTM Price-to-Sale (P/S) ratio is 199.26 while its Price-to-Book (P/B) ratio in mrq is 8.70. Its current Enterprise Value per Revenue stands at 191.467 whereas that against EBITDA is -13.935.
Stock Price History:
The Beta on a monthly basis for CNTA is 1.58, which has changed by 0.37569058 over the last 52 weeks, in comparison to a change of 0.13724327 over the same period for the S&P500. Over the past 52 weeks, CNTA has reached a high of $24.57, while it has fallen to a 52-week low of $9.60. The 50-Day Moving Average of the stock is 12.00%, while the 200-Day Moving Average is calculated to be 40.08%.
Shares Statistics:
According to the various share statistics, CNTA traded on average about 1.23M shares per day over the past 3-months and 1133510 shares per day over the past 10 days. A total of 133.91M shares are outstanding, with a floating share count of 85.14M. Insiders hold about 36.42% of the company’s shares, while institutions hold 56.11% stake in the company. Shares short for CNTA as of 1759190400 were 4991915 with a Short Ratio of 4.06, compared to 1756425600 on 5268748. Therefore, it implies a Short% of Shares Outstanding of 4991915 and a Short% of Float of 4.38.
Earnings Estimates
Investors are keenly observing as 6.0 analysts analyze and rate . The current performance of Centessa Pharmaceuticals plc ADR (CNTA) in the stock market.The consensus estimate for the next quarter is -$0.41, with high estimates of -$0.38 and low estimates of -$0.44.
Analysts are recommending an EPS of between -$1.33 and -$1.46 for the fiscal current year, implying an average EPS of -$1.39. EPS for the following year is -$1.67, with 8.0 analysts recommending between -$1.37 and -$2.03.
